RxDoctor Payments Data

Omar Baber, MD

Cardiovascular Disease · Oklahoma City, OKNPI 1457799850

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (56.4%), grants and education — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by Abbott at 42.4% of the total. Reporting peaked in 2022 at $3,639 and has fallen 79.7% since, to $739 in 2025.

$5,651in general payments, 2019–2025

Across 69 payments — averaging $81.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$2K
  • Abiomed$910
  • Medtronic$549
  • Teleflex LLC$448
  • Boston Scientific$382
  • Stryker$221
  • plus $744 from 12 others

What the payments were for

  • Grants$2,25040%
  • Food & beverage$3,18656%
  • Education$2144%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,651 in reported general payments places this provider in the 70th percentile of 164 cardiovascular disease providers in Oklahoma.

See all cardiovascular disease providers in Oklahoma

Medicare billing

Part B allowed, 2024
$76,519
Medicare patients
944
Services billed
1,624

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban74$65,469
BrilintaTicagrelor25$17,297
EntrestoSacubitril/Valsartan17$15,133
Rosuvastatin Calcium72$1,924
Metoprolol Succinate85$1,837
Carvedilol37$817
Amlodipine Besylate68$698
Atorvastatin Calcium57$667
Metoprolol Tartrate43$421
Losartan Potassium18$353
Ezetimibe19$338
ClopidogrelClopidogrel Bisulfate22$328
Furosemide55$244
Spironolactone24$195
Isosorbide Mononitrate ErIsosorbide Mononitrate24$146

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$44$15,13317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 164 cardiovascular disease providers in Oklahoma.

Other cardiovascular disease in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →